Mersana Therapeutics Inc. (MRSN)

Business: Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.

IPO Date: 28-Jun-2017

Pres, CEO & Director: Ms. Anna Protopapas M.B.A.

Sr. VP & CFO: Mr. Brian C. DeSchuytner

Listing: NASDAQ: MRSN

Country: United States

Headquarters: Cambridge, MA

Website: https://www.mersana.com

Market cap: $484.96 Mln

Revenue (TTM): $2.07 Mln

Earnings (TTM): $-182.63 Mln

Cash: $230.06 Mln

Total Debt: $37.67 Mln

Insider's Holding: 1.13%

Liquidity: Low

52 Week range: $2.68 - 14.80

Shares outstanding: 96,991,296

7 Years Aggregate:

• CFO: $-358.37 Mln
• EBITDA: $-411.33 Mln
• Net Profit: $-419.41 Mln